2026-04-27T19:55:10Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/634432024-12-16T07:15:36Zcom_10324_1133com_10324_931com_10324_894col_10324_1209

Fernández Lázaro, Diego Iglesias Lázaro, María Garrosa, Evelina Rodríguez García, Saray Jerves Donoso, David Gutiérrez Abejón, Eduardo Jorge Finnigan, Conrado 2023-12-04T09:21:22Z 2023-12-04T09:21:22Z 2023 Medicina, 2023, Vol. 59, Nº. 2, 247 1648-9144 https://uvadoc.uva.es/handle/10324/63443 10.3390/medicina59020247 247 2 Medicina 59 1648-9144 Producción Científica Scleroderma or systemic sclerosis (SSc) is an autoimmune disease affecting the connective tissue, characterized by fibrosis of the skin and internal organs. There is currently no curative treatment available, so therapeutic action is aimed at a symptomatic treatment of the affected organs. The development of biotechnology has made it possible to implement certain biological drugs that could represent a window of opportunity to modulate the evolution and symptomatology of scleroderma with greater efficacy and less toxicity than conventional treatments. This study aimed to review the current evidence critically and systematically on the effects of biological drugs on the pulmonary function, skin disease, and health status of patients afflicted by diffuse cutaneous systemic sclerosis (dcSSc). Three electronic databases (Pubmed, Dialnet, and Cochrane Library Plus) were systematically searched until the cut-off date of October 2022. The review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and included original articles in English and Spanish with a controlled trial design, comparing biological drug treatments (tocilizumab, belimumab, riociguat, abatacept, and romilkimab) with a control group. The methodological quality of the studies was assessed using the McMaster quantitative form and the PEDro scale. A total of 383 studies were identified, 6 of them met the established criteria and were included in the present systematic review. A total of 426 patients treated with tocilizumab, belimumab, riociguat, abatacept, and romilkimab were included. The results showed substantial non-significant (p < 0.05) improvement trends after treatment with the biological drugs included in this review for the modified Rodnan Scale Value, Forced Vital Capacity, and Carbon Monoxide Diffusion Test; however, no benefits were shown on the Health Assessment Questionnaire–Disability Index when compared to the control group. Biological drugs, therefore, maybe a new therapeutic strategy for dcSSc and could be recommended as an additional and/or adjunctive treatment that promotes anti-fibrotic activity. This review could further define the clinical rationale for the use of biologics in the treatment of dcSSc and could provide key details on the study protocol, design, and outcome reporting. Caja Rural de Soria - (project SO-12-2022) application/pdf eng info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/4.0/ © 2023 The authors Atribución 4.0 Internacional Scleroderma (Disease) Esclerodermia (Enfermedad) Autoimmune diseases Enfermedades autoinmunes Skin - Diseases Piel - Enfermedades Systemic scleroderma Immunology Dermatology Rheumatology Respiratory organs - Diseases Pulmonary function tests Lungs - Diseases Organos respiratorios - Enfermedades Pulmones - Enfermedades Health status indicators Biological products - Therapeutic use Drugs - Therapeutic use Medicamentos - Uso Public health 2412 Inmunología 3201.06 Dermatología 3205.09 Reumatología 3205.08 Enfermedades Pulmonares 3212 Salud Publica Impact of innovative treatment using biological drugs for the modulation of diffuse cutaneous systemic sclerosis: A systematic review info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion https://www.mdpi.com/1648-9144/59/2/247 SI